NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Clinical trials for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE explained in plain language.
Never miss a new study
Get alerted when new NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE trials appear
Sign up with your email to follow new studies for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Triple-Drug combo tame an aggressive lymphoma without harsh chemo?
Disease control CompletedThis phase 2 trial is testing whether a combination of three drugs—sintilimab, pegaspargase, and anlotinib—can effectively treat stage IV extranodal NK/T-cell lymphoma in patients who are not healthy enough for high-intensity chemotherapy. The study enrolls adults with newly diag…
Matched conditions: NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Phase: PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Three-Drug cocktail boost Radiation's power against a rare lymphoma?
Disease control CompletedThis trial is testing whether combining three drugs—camrelizumab, apatinib, and pegaspargase—with radiation therapy can improve outcomes for people with early-stage natural killer/T-cell lymphoma, a rare type of cancer. The study includes about 61 patients with stage IE or IIE di…
Matched conditions: NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Phase: NA • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC